Bayer Cropscience India Limited (BAYERCROP) AI Stock Analysis

• Market Cap: ₹217.34B
• Dividend Yield: 2.72%
• Average Volume (3M): 2.83K
• Price to Earnings (P/E): 36.7
• Beta (1Y): 1.07
• Revenue Growth: 15.23%
• EPS Growth: -11.06%
• Country: IN
• Employees: 1,317
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Agricultural Inputs
• EPS (TTM): 33.40
• Shares Outstanding: 44,942,093
• 10 Day Avg. Volume: 4,614
• 30 Day Avg. Volume: 2,834
• PEG Ratio: -1.63
• Price to Book (P/B): 7.59
• Price to Sales (P/S): 3.95
• P/FCF Ratio: 83.41
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 62 Neutral
• Price Target: ₹5,375.00 ▲(16.97% Upside)

Bayer Cropscience India Limited's overall stock score is driven primarily by its strong financial performance, particularly its robust balance sheet and cash reserves. However, technical analysis indicates bearish momentum, and the stock's high valuation relative to peers suggests limited upside potential. Addressing margin pressures will be key to improving future performance.

Bayer Cropscience India Limited Business Overview & Revenue Model

Company Description

Bayer CropScience Limited engages in the manufacture, sale, and distribution of insecticides, fungicides, herbicides, and various other agrochemical products and corn seeds in India, Germany, Bangladesh, and internationally. It provides medicines primarily in the therapeutic areas of cardiology, gynecology, diabetes, oncology, and ophthalmology; and diagnostic imaging equipment and other contrast agents, including computed tomography, X-Ray, and magnetic resonance imaging devices. In addition, the company offers consumer health products that are used as a daily health solution to treat minor illnesses, as well as sells and distributes hybrid seeds, such as corn and paddy. Further, it provides digital farming products comprising FarmRiseTM and digital prediction systems that integrate data from farm equipment, satellites, field sensors, irrigation systems, drones, and other input sources and then analyze that data to allow farmers to make decisions through data science and predictive analytics. The company also exports its products. Bayer CropScience Limited was incorporated in 1958 and is based in Thane, India.

How the Company Makes Money

Bayer Cropscience India Limited generates revenue primarily through the sale of agricultural chemicals, including crop protection products such as herbicides and insecticides, as well as seeds and biotechnology products. The company's revenue model is based on a combination of direct sales to farmers and distribution through a network of retailers and agricultural cooperatives. Key revenue streams include product sales in both domestic and export markets, with significant contributions from premium products that offer advanced formulations and sustainable solutions. Additionally, BAYERCROP engages in partnerships with research institutions, agricultural organizations, and other stakeholders to enhance product development and market reach, further contributing to its earnings.

Bayer Cropscience India Limited Financial Statement Overview

Summary

Bayer Cropscience India Limited demonstrates a strong financial position with stable revenue growth and a solid balance sheet featuring low leverage and high equity. However, the decrease in profit margins and operating cash flow in 2025 presents a challenge. The company's strong cash reserves and capital structure mitigate risks, but addressing margin pressures is crucial for sustained growth.

Income Statement

Bayer Cropscience India Limited has shown consistent revenue growth, with Total Revenue increasing from 2020 to 2025. However, gross profit margin declined significantly from 45.36% in 2024 to 28.14% in 2025, indicating rising cost pressures or pricing issues. Net profit margin also decreased from 14.50% in 2024 to 10.38% in 2025. Despite these declines, the company maintains a solid EBIT margin in 2025 at 11.05% and an EBITDA margin of 14.79%, reflecting efficient operations.

Balance Sheet

The balance sheet of Bayer Cropscience India Limited is robust, with a low debt-to-equity ratio of 0.04 in 2025, indicating minimal leverage risk. The equity ratio is strong at 54.35%, showcasing a healthy capital structure. The company also maintains high levels of cash and equivalents, supporting liquidity and stability. Return on Equity (ROE) decreased slightly to 19.92% in 2025, yet remains impressive.

Cash Flow

Cash flow performance is mixed; operating cash flow decreased from 2024 to 2025, which could impact future investments. However, free cash flow generation is stable, and the free cash flow to net income ratio is robust, indicating good cash conversion. Despite the decline in operating cash flow, the company has maintained strong free cash flow growth in prior years.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	57.57B	54.73B	51.06B	51.40B	47.34B	42.61B
Gross Profit	21.57B	20.59B	21.81B	23.09B	20.57B	17.99B
EBITDA	6.81B	6.43B	9.43B	8.86B	7.90B	7.80B
Net Income	5.92B	5.68B	7.41B	7.58B	6.45B	4.93B
Balance Sheet
Total Assets	0.00	52.46B	45.97B	46.79B	43.53B	42.39B
Cash, Cash Equivalents and Short-Term Investments	9.21B	9.29B	12.11B	9.02B	8.19B	12.57B
Total Debt	0.00	1.05B	471.00M	735.00M	864.00M	263.00M
Total Liabilities	-28.50B	23.95B	17.48B	19.66B	18.29B	16.89B
Stockholders Equity	28.50B	28.50B	28.49B	27.12B	25.24B	25.50B
Cash Flow
Free Cash Flow	0.00	2.59B	9.06B	5.32B	1.60B	6.45B
Operating Cash Flow	0.00	3.00B	9.52B	6.09B	2.15B	6.87B
Investing Cash Flow	0.00	389.00M	4.00M	833.00M	642.00M	67.00M
Financing Cash Flow	0.00	-6.10B	-6.56B	-6.13B	-7.03B	-5.56B

Bayer Cropscience India Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4595.35
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BAYERCROP, the sentiment is Negative. The current price of 4595.35 is below the 20-day moving average (MA) of 4944.21, below the 50-day MA of 5042.69, and below the 200-day MA of 5223.60, indicating a bearish trend. The MACD of -95.52 indicates Positive momentum. The RSI at 28.36 is Positive, neither overbought nor oversold. The STOCH value of 29.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:BAYERCROP.

Bayer Cropscience India Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PIIND	74 Outperform	₹558.73B	34.67	―	0.43%	-0.19%	-7.79%
COROMANDEL	67 Neutral	₹638.98B	26.57	―	0.56%	32.88%	75.74%
UPL	64 Neutral	₹620.26B	28.18	―	0.80%	8.14%	―
CHAMBLFERT	62 Neutral	₹192.74B	11.01	―	2.05%	19.70%	22.23%
BAYERCROP	62 Neutral	₹217.34B	36.68	―	2.72%	15.23%	-11.06%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
SUMICHEM	59 Neutral	₹239.71B	44.18	―	0.25%	8.69%	12.26%